Department of Internal medicine, Yoshikawa Central General Hospital, Saitama, Japan.
Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
Hum Vaccin Immunother. 2021 Aug 3;17(8):2661-2669. doi: 10.1080/21645515.2021.1875760. Epub 2021 Apr 20.
A national routine pneumococcal pneumonia immunization program started in Japan in 2014. It targeted the population aged ≥65 years and used a 23-valent pneumococcal polysaccharide vaccine; PPSV23. However, its effectiveness was not well defined because of the lack of a comprehensive database on the PPSV23 vaccination status of each subject. We used interrupted time-series analyses to assess the changes in the incidence and prognosis of elderly patients hospitalized for pneumonia before and after initiation of the program. First, we estimated the PPSV23 coverage rates in subjects aged ≥65 years based on the number of shipped PPSV23 syringes and the estimated population in each prefecture. The estimated coverage rates reached around 40% in 2014 for the 3 Tohoku prefectures, while those in the other prefectures remained below 20%. After the national routine immunization program started, the estimated coverage rate increased significantly in every prefecture and exceeded 40% in 2017. Next, we aggregated the data extracted from the Japanese Diagnosis Procedure Combination database from April 2011 through February 2017 for hospitalized pneumonia patients aged ≥65 years. The data included data from 655,746 patients, excluding those in the 3 Tohoku prefectures. Interrupted time-series analyses found no change in the incidence of hospitalized pneumonia patients and in-hospital mortality after the vaccination program, but there was a decrease in the in-hospital mortality of pneumonia patients with severe comorbidities defined by the modified Charlson comorbidity index. These results suggest an association between the vaccination program and an improved outcome in hospitalized elderly pneumonia patients with severe comorbidities in Japan.
日本于 2014 年启动了一项全国性常规肺炎球菌性肺炎免疫计划。该计划针对年龄≥65 岁的人群,使用 23 价肺炎球菌多糖疫苗(PPSV23)。然而,由于缺乏关于每个研究对象 PPSV23 接种状况的综合数据库,其效果并未得到很好的定义。我们使用中断时间序列分析来评估该计划启动前后老年住院肺炎患者的发病率和预后变化。首先,我们根据每个县发货的 PPSV23 注射器数量和估计的人口数,估计≥65 岁人群中 PPSV23 的接种率。在 2014 年,3 个东北地区的县的估计接种率达到了 40%左右,而其他县的接种率仍低于 20%。在全国常规免疫计划启动后,每个县的估计接种率显著增加,并在 2017 年超过 40%。接下来,我们汇总了 2011 年 4 月至 2017 年 2 月从日本诊断程序组合数据库中提取的≥65 岁住院肺炎患者的数据。这些数据包括来自 655746 名患者的数据,不包括东北地区的 3 个县。中断时间序列分析发现,接种计划后,住院肺炎患者的发病率和住院死亡率没有变化,但改良 Charlson 合并症指数定义的严重合并症肺炎患者的住院死亡率有所下降。这些结果表明,在日本,该疫苗接种计划与严重合并症的住院老年肺炎患者的转归改善有关。